Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
UCBCares: Providing Dedicated Patient Support
Clinical studies at UCB: How are medicines made and tested?
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
Twitter Feed
-
Today we have announced positive new Phase 3 results from a #psoriasis #clinicalstudy - the second in just four weeks. The results demonstrate our commitment to advancing immunodermatology and providing new treatment options for patients with unmet needs
— UCB News (@ucb_news) 15.11.2019 -
Tomorrow's innovative therapies offer fresh hope. We launched #UCBVentures in 2017 to explore the medicines of tomorrow. https://t.co/HX4ZwpJLUn #InspiredByPatients #DrivenByScience https://t.co/uzdYtEK9J7
— UCB News (@ucb_news) 15.11.2019 -
Today we are announcing positive results from BE READY, a Phase 3 #clinicaltrial evaluating the efficacy and safety of an investigational treatment in adult patients with moderate-to-severe plaque #psoriasis https://t.co/MDQp2anwZP https://t.co/Sp9DSvMBxi
— UCB News (@ucb_news) 15.11.2019
